PreveCeutical Announces Amendment to $3.28 Million Non-Brokered Private Placement
Vancouver, British Columbia--(Newsfile Corp. - January 3, 2018) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) (the "Company" or "PreveCeutical") announces that it has amended the terms of its previously announced non-brokered private placement (the "Financing") of $0.75 units (see news release dated November 22, 2017). Under the amended terms of the Financing, the Company will offer up to 6.6 million units (each, a "Unit") at the price of $0.50 per Unit. Each Unit will...
2018-01-03 7:30 PM EST
PreveCeutical Medical Inc. Announces $3.28 Million Fully Subscribed Private Placement
Vancouver, British Columbia--(Newsfile Corp. - November 22, 2017) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) (the "Company" or "PreveCeutical"), announces a fully subscribed non-brokered private placement (the "Financing") of up to 4,377,776 units (each, a "Unit") at a price of $0.75 per Unit to raise gross proceeds of $3,283,332. Each Unit will consist of one common share of the Company and one warrant, with each warrant entitling the holder thereof to purchase one...
2017-11-22 3:05 AM EST
PreveCeutical Receives Australian State Approval to Acquire and Use Cannabis as Part of Its Research and Development Program
Vancouver, British Columbia--(Newsfile Corp. - November 1, 2017) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) (the "Company" or "PreveCeutical") is pleased to announce that it has received approval (the "Approval") from the Environmental Hazards Unit of the Queensland Government (the Australian state-level authority) to acquire, store and use high-quality cannabis oil and dried cannabis plant extracts. The Approval is a significant milestone which enables PreveCeutical's...
2017-11-01 3:05 AM EDT
PreveCeutical Medical Inc. Announces Appointment of Dr. Makarand Jawadekar to its Board of Directors
Vancouver, British Columbia--(Newsfile Corp. - October 26, 2017) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) (the "Company" or "PreveCeutical"), announces the appointment of Dr. Makarand Jawadekar as a director of the Company and the resignation of Mr. Brian Harris as a director and the Vice President of Corporate Development of the Company, effective October 24, 2017. Dr. Jawadekar completed his Ph.D. in Pharmaceutics at the University of Minnesota. He is currently an...
2017-10-26 9:30 AM EDT
PreveCeutical Medical Inc. Announces Filing of Amended and Restated Interim Financial Statements
Vancouver, British Columbia--(Newsfile Corp. - October 23, 2017) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) (the "Company" or "PreveCeutical"), announces, that as a result of a review by the British Columbia Securities Commission, the Company has filed amended and restated financial statements (the "Amended Financial Statements") together with an amended management's discussion and analysis (together with the Amended Financial Statements, the "Amended Financial...
2017-10-23 8:33 PM EDT
PreveCeutical Applies to List on the TSX Venture Exchange as a Tier 2 Issuer
Vancouver, British Columbia--(Newsfile Corp. - September 25, 2017) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) (the "Company" or "PreveCeutical") announces that the Company has filed an application to list its common shares on the TSX Venture Exchange (the "TSX-V") as a tier 2 issuer. About PreveCeutical Medical Inc. PreveCeutical is a health sciences company that develops innovative preventive therapies utilizing organic and nature identical products. PreveCeutical...
2017-09-25 3:05 AM EDT
PreveCeutical Announces Strategic R&D Supply Agreement
Vancouver, British Columbia--(Newsfile Corp. - September 21, 2017) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) (the "Company" or "PreveCeutical") is pleased to announce that it has entered into a strategic research and development supply agreement dated effective September 18, 2017 (the "Supply Agreement") with a licensed producer of medical cannabis (the "LP") under Health Canada's Access to Cannabis for Medical Purposes Regulations, whereby the LP will supply samples...
2017-09-21 3:05 AM EDT
PreveCeutical Begins Trading on the OTCQB Venture Marketplace
Vancouver, British Columbia--(Newsfile Corp. - September 18, 2017) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) (the "Company" or "PreveCeutical") announces that the Company's application to have its common shares listed on the OTCQB Venture Marketplace ("OTCQB") in the United States has been approved and that the Company's common share began trading on September 15, 2017, under the symbol "PRVCF". The OTCQB is for early-stage and developing United States and...
2017-09-18 3:05 AM EDT
PreveCeutical Launches New Corporate Website
Vancouver, British Columbia--(Newsfile Corp. - September 15, 2017) - PreveCeutical Medical Inc. (CSE: PREV) (OTC Pink: PRVCF) (FSE: 18H) (the "Company" or "PreveCeutical") is pleased to announce the launch of a new corporate website - www.PreveCeutical.com. The new website has been optimized to cater to both desktop and mobile users. In an organized layout, visitors across all platforms are able to efficiently access information on PreveCeutical's innovative research and development programs,...
2017-09-15 3:05 AM EDT
PreveCeutical Engages the Susan Blond Group Inc. for Publicity Services and Appoints Ms. Susan Blond as Director of Publicity
Vancouver, British Columbia--(Newsfile Corp. - September 13, 2017) - PreveCeutical Medical Inc. (CSE: PREV) (OTC Pink: PRVCF) (FSE: 18H) (the "Company" or "PreveCeutical"), announces the engagement of the Susan Blond Group Inc. (the "Susan Blond Group") to provide publicity services and the appointment of Ms. Susan Blond as the Company's Director of Publicity. Ms. Blond, principal of the Susan Blond Group, will assist PreveCeutical in initiating, implementing and executing the Company's...
2017-09-13 3:05 AM EDT
PreveCeutical(TM) Medical and Sports 1 Marketing Announce Joint Venture to Develop a Therapy for Concussions
Vancouver, British Columbia--(Newsfile Corp. - August 30, 2017) - PreveCeutical Medical Inc. (CSE: PREV) (OTC Pink: PRVCF) (FSE: 18H) (the "Company" or "PreveCeutical"), and Sports 1 Marketing ("S1M") announces a joint venture to develop a therapy geared towards athletes who suffer from concussions (Mild Traumatic Brain Injury) ("TBI"). Through PreveCeutical's current Research and Development ("R&D") program connected to the Caribbean Blue Scorpion venom, PreveCeutical and S1M believe that...
2017-08-30 3:05 AM EDT
PreveCeutical(TM) Medical Begins Trading on the OTC Market
Vancouver, British Columbia--(Newsfile Corp. - August 16, 2017) - PreveCeutical Medical Inc. (CSE: PREV) (OTC Pink: PRVCF) (FSE: 18H) (the "Company" or "PreveCeutical"), announces the quotation of its common shares for trading on the OTC Pink market, under the symbol "PRVCF". In connection with the quotation of its shares on the OTC, the Company is completing its filings for the quotation of its shares on the OTCQB market. The Company has also made an application for its common shares to be...
2017-08-16 3:05 AM EDT
PreveCeutical(TM) Medical Inc. Announces Requisitions to Acquire State-of-the-Art Instrumentation Expediting Suite of Research and Developments Programs
Vancouver, British Columbia--(Newsfile Corp. - August 14, 2017) - PreveCeutical™ Medical Inc. (CSE: PREV) (FSE: 18H) (the "Company" or "PreveCeutical") announces the Company has acquired four new key instruments to assist in expediting PreveCeutical's current pipeline of innovative Research and Development Programs (R&D). PreveCeutical anticipates delivery and commissioning of all four systems in the next four to six weeks. R&D Programs Dual Gene Therapy This program paves the way for...
2017-08-14 3:05 AM EDT